Pathlight MRD Test
Early-Stage Breast Cancer
Key Facts
About SAGA Diagnostics
SAGA Diagnostics is a commercial-stage diagnostics company pioneering a next-generation, tumor-informed MRD detection platform. Its core technology, Pathlight™, utilizes patient-specific structural variants (SVs) identified via whole-genome sequencing, coupled with digital PCR, to achieve industry-leading sensitivity and specificity for monitoring circulating tumor DNA. Initially launched for early-stage breast cancer in the U.S. and recently expanded to colorectal cancer, SAGA aims to provide critical data to guide treatment decisions and partners with biopharma companies on clinical development programs. The company's validated approach addresses key limitations of first-generation MRD tests, particularly in cancers like ER+ breast cancer.
View full company profileAbout SAGA Diagnostics
SAGA Diagnostics is a commercial-stage diagnostics company pioneering a next-generation, tumor-informed MRD detection platform. Its core technology, Pathlight™, utilizes patient-specific structural variants (SVs) identified via whole-genome sequencing, coupled with digital PCR, to achieve industry-leading sensitivity and specificity for monitoring circulating tumor DNA. Initially launched for early-stage breast cancer in the U.S. and recently expanded to colorectal cancer, SAGA aims to provide critical data to guide treatment decisions and partners with biopharma companies on clinical development programs. The company's validated approach addresses key limitations of first-generation MRD tests, particularly in cancers like ER+ breast cancer.
View full company profileTherapeutic Areas
Other Early-Stage Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MammaPrint/BluePrint Clinical Utility Expansion | Agendia | Commercial |
| Real-World Evidence (FLEX Study) | Agendia | Observational Study |
| OncoTect for Taxanes in Early-Stage Breast Cancer | Aida Oncology | Clinical Validation |
| GammaPod Commercialization & Clinical Adoption | Xcision Medical Systems | Commercial |
| Signatera™ MRD (Adjuvant De-escalation) | Natera | Clinical Utility Study |